ALVR - Allovir Inc

-

$undefined

N/A

(N/A)

Allovir Inc NasdaqCM:ALVR Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Location: 1100 Winter Street, Waltham, MA, 02451, United States | Website: https://www.allovir.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-69.08M

Cash

118.3M

Avg Qtr Burn

-16.93M

Short % of Float

6.75%

Insider Ownership

9.29%

Institutional Own.

13.66%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Posoleucel Details
BK virus, Kidney transplantation

Phase 2

Update

ALVR106 Details
Respiratory syncytial virus, Influenza, Human metapneumovirus, Parainfluenza virus

Failed

Discontinued

Posoleucel Details
Epstein-Barr virus, Human herpesvirus 6, BK virus, Adenovirus, Cytomegalovirus

Failed

Discontinued

Failed

Discontinued

Posoleucel Details
Virus-associated hemorrhagic cystitis , Adenovirus

Failed

Discontinued